Arming parvoviruses with CpG motifs to improve their oncosuppressive capacity

International Journal of Cancer

Volumn 122, Issue 12, 2008, Pages 2880-2884

  Raykov, Zahari ^a   Grekova, Svetlana ^a   Leuchs, Barbara ^a   Aprahamian, Marc ^b   Rommelaere, Jean ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b IRCAD   (France)

Author keywords

Cancer; CpG motif; Oncolytic; Parvovirus; TLR 9

Indexed keywords

B7 ANTIGEN; CD86 ANTIGEN; CPG OLIGODEOXYNUCLEOTIDE; GAMMA INTERFERON; TOLL LIKE RECEPTOR 9; VIRUS DNA; VIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL ACTIVATION; CELLULAR IMMUNITY; CONTROLLED STUDY; DENDRITIC CELL; EX VIVO STUDY; GENETIC ENGINEERING; GENETIC VARIABILITY; IMMUNOGENICITY; IMMUNOSTIMULATION; IN VITRO STUDY; INFECTION; LIVER CELL CARCINOMA; LUNG METASTASIS; MEDIASTINUM LYMPH NODE; MOUSE; NONHUMAN; PARVOVIRUS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; VIRUS GENOME; VIRUS REPLICATION; WILD TYPE;

ANIMALS; BASE SEQUENCE; CELL LINE; CPG ISLANDS; DNA PRIMERS; DNA, VIRAL; ONCOLYTIC VIROTHERAPY; PARVOVIRUS; RATS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 43049124141     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23472     Document Type: Article

References (23)

1. Rommelaere J, Giese N, Cziepluch C, Cornelis JJ. Parvoviruses as anticancer agents. In: Sinkovics JG, Horvath JC, eds. Viral therapy of human cancers. New York: Marcel Dekker, 2005;627 p.
2. Russell SJ, Brandenburger A, Flemming CL, Collins MK, Rommelaere J. Transformation-dependent expression of interleukin genes delivered by a recombinant parvovirus. J Virol 1992;66:2821-8.
3. Raykov Z, Grekova S, Galabov AS, Balboni G, Koch U, Aprahamian M, Rommelaere J. Combined oncolytic and vaccination activities of parvovirus H-1 in a metastatic tumor model. Oncol Rep 2007;17: 1493-9.
4. Krieg AM. Therapeutic potential of toll-like receptor 9 activation. Nat Rev Drug Discov 2006;5:471-84.
5. Hartmann G, Weiner GJ, Krieg AM. CpG DNA: a potent signal for growth, activation, and maturation of human dendritic cells. Proc Natl Acad Sci USA 1999;96:9305-10.
6. Meng Y, Carpentier AF, Chen L, Boisserie G, Simon JM, Mazeron JJ, Delattre JY. Successful combination of local CpG-ODN and radiotherapy in malignant glioma. Int J Cancer 2005;116:992-7.
7. Carpentier A, Laigle-Donadey F, Zohar S, Capelle L, Behin A, Tibi A, Martin-Duverneuil N, Sanson M, Lacomblez L, Taillibert S, Puybasset L, Van Effenterre R, et al. Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma. Neurooncology 2006;8:60-6.
8. Zipris D, Lien E, Nair A, Xie JX, Greiner DL, Mordes JP, Rossini AA. TLR9-signaling pathways are involved in Kilham rat virus-induced autoimmune diabetes in the biobreeding diabetes-resistant rat. J Immunol 2007;178:693-701.
9. Karlin S, Doerfler W, Cardon LR. Why is CpG suppressed in the genomes of virtually all small eukaryotic viruses but not in those of large eukaryotic viruses? J Virol 1994;68:2889-97.
10. Schulz O, Diebold SS, Chen M, Naslund TI, Nolte MA, Alexopoulou L, Azuma YT, Flavell RA, Liljestrom P, Reis e Sousa C. Toll-like receptor 3 promotes cross-priming to virus-infected cells. Nature 2005;433:887-92.
11. Raykov Z, Balboni G, Aprahamian M, Rommelaere J. Carrier cell-mediated delivery of oncolytic parvoviruses for targeting metastases. Int J Cancer 2004;109:742-9.
12. Fischer SF, Rehm M, Bauer A, Hofling F, Kirschnek S, Rutz M, Bauer S, Wagner H, Hacker G. Toll-like receptor 9 signaling can sensitize fibroblasts for apoptosis. Immunol Lett 2005;97:115-22.
13. Lundberg P, Welander P, Han X, Cantin E. Herpes simplex virus type 1 DNA is immunostimulatory in vitro and in vivo. J Virol 2003;77:11158-69.
14. Faisst S, Faisst SR, Dupressoir T, Plaza S, Pujol A, Jauniaux JC, Rhode SL, Rommelaere J. Isolation of a fully infectious variant of parvovirus H-1 supplanting the standard strain in human cells. J Virol 1995;69:4538-43.
15. Sivori S, Carlomagno S, Moretta L, Moretta A. Comparison of different CpG oligodeoxynucleotide classes for their capability to stimulate human NK cells. Eur J Immunol 2006;36:961-7.
16. Christensen J, Cotmore SF, Tattersall P. Parvovirus initiation factor PIF: a novel human DNA-binding factor which coordinately recognizes two ACGT motifs. J Virol 1997;71:5733-41.
17. Dalpke A, Frank J, Peter M, Heeg K. Activation of toll-like receptor 9 by DNA from different bacterial species. Infect Immun 2006;74:940-6.
18. Moehler MH, Zeidler M, Wilsberg V, Cornelis JJ, Woelfel T, Rommelaere J, Galle PR, Heike M. Parvovirus H-1-induced tumor cell death enhances human immune response in vitro via increased phagocytosis, maturation, and cross-presentation by dendritic cells. Hum Gene Ther 2005;16:996-1005.
19. Sugiyama T, Gursel M, Takeshita F, Coban C, Conover J, Kaisho T, Akira S, Klinman DM, Ishii KJ. CpG RNA: identification of novel single-stranded RNA that stimulates human CD14+CD11c+ monocytes. J Immunol 2005;174:2273-9.
20. Ballas ZK. Modulation of NK cell activity by CpG oligodeoxynucleotides. Immunol Res 2007;39:15-21.
21. Moron VG, Rueda P, Sedlik C, Leclerc C. In vivo, dendritic cells can cross-present virus-like particles using an endosome-to-cytosol pathway. J Immunol 2003;171:2242-50.
22. Kanzler H, Barrat FJ, Hessel EM, Coffman RL. Therapeutic targeting of innate immunity with toll-like receptor agonists and antagonists. Nat Med 2007;13:552-9.
23. Heikenwalder M, Polymenidou M, Junt T, Sigurdson C, Wagner H, Akira S, Zinkernagel R, Aguzzi A. Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration. Nat Med 2004;10:187-92.